Bessemer Group
KALV

Bessemer Group’s KalVista Pharmaceuticals KALV Stock Holding History

Bessemer Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
10
– – ﹤0.01% 2606
2025
Q4 		$0 Hold
10
– – ﹤0.01% 2627
2025
Q3 		$0 Buy
+10
New +$138 ﹤0.01% 2609
2024
Q4 		– Sell
-45
Closed -$1K – 2570
2024
Q3 		$1K Buy
+45
New +$566 ﹤0.01% 2447

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bessemer Group's KALV Position: Q1 2026 in Review

Bessemer Group held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2606.

Bessemer Group first reported a position in KALV in Q3 2024 and has held it in 4 quarters since. The position peaked at $1K in Q3 2024. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Bessemer Group held 10 shares of KalVista Pharmaceuticals worth $0 as of Q1 2026.
  • Bessemer Group left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2606 holding.
  • Bessemer Group first reported a position in KalVista Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Bessemer Group's KalVista Pharmaceuticals position peaked at $1K in Q3 2024.
  • 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.